Summa Therapeutics Reports Positive Outcomes With Injectable Angioplasty Balloon Catheter

Summa Therapeutics LLC is reporting success with its Finesse Injectable balloon catheter.

First in-man injectable angioplasty procedures have been successfully performed on patients with below-the-knee peripheral arterial disease (PAD) using the Finesse platform. The company claims its Summa Finesse Injectable catheter is the industry’s first hybrid diagnostic and therapeutic angioplasty balloon catheter developed to treat patients at risk of limb loss due to below-knee PAD. It was designed to improve the efficiency of peripheral angioplasty procedures by reducing equipment and contrast needs.
 
Each year, more than 140,000 lower extremity amputations occur in the United States, mostly due to circulation issues. For patients at risk of amputation due to poor circulation, angioplasty procedures below the knee can be limb-saving but these procedures are complex and typically require numerous exchanges of specialized equipment during a procedure.
 
The Summa Finesse Injectable platform provides contrast injection on the fly, enabling users to move seamlessly from injection to balloon inflation throughout complex procedures. This distinct operator convenience streamlines the procedure and reduces the need for equipment. All users reported that the injection ability exceeded expectations.
 
Angioplasty procedures below the knee also require X-ray contrast, which can cause damage to kidney function. This is an especially critical issue because many patients undergoing angioplasty procedures below the knee have diabetes and kidney dysfunction. Operators reported the Summa Finesse Injectable catheter did not require as much X-ray contrast, with 100% of procedures requiring less contrast than typically used with conventional devices. In the calf, ultra-low contrast angiograms were obtained with as little as 1 ml equivalent of contrast.
 
The first-in-man procedures took place at Mt. Sinai hospital in New York City by Drs. Rahul Patel and Robert Lookstein, and at the Advanced Vascular and Interventional Services office-base laboratory in West Orange, N.J. by Drs. John Rundback and Kevin Herman.
 
“The Summa balloon platform is a game changer that provides several unique advantages,” said Rundback, an interventional radiologist and vascular specialist. “In our busy limb salvage practice, it will be an important tool.”
 
The Summa Finesse Injectable is a multifunctional catheter that serves as a crossing catheter, diagnostic angiography catheter, and angioplasty catheter to reduce equipment and contrast needs. It was noted that in many cases with the Summa Finesse catheter functioning as a crossing catheter, microcatheters were not needed to cross arterial obstructions.
 
“Summa’s system makes below-knee angioplasty cases easier compared to a conventional setup,” said Herman, a nationally acclaimed interventional radiologist. “I start with Finesse and use it to perform angiography, cross lesions, and do serial angioplasties of multiple arterial segments in the calf—all with the same catheter. It’s a better designed system for below-knee angioplasty.”
 
“In the first cases, expectations were met or exceeded, including improved procedural efficiency and lower equipment needs,” Summa Therapeutics CEO Dr. Timothy Murphy said. “All users reported using less contrast and yet angiographic quality was described as excellent.”

The Summa Finesse Injectable is the first hybrid catheter launched in the planned line of interventional radiology devices from Summa Therapeutics.
 
Summa Therapeutics LLC is a commercial-stage medical device company developing solutions in cardiovascular interventional medicine.